查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2018-2028年腫瘤學和免疫學流式細胞術市場 - 全球行業規模、佔有率、趨勢、競爭、機會和預測，按類型、按技術、按產品、按應用、按最終用戶、按地區細分
市場調查報告書
商品編碼
1309225

2018-2028年腫瘤學和免疫學流式細胞術市場 - 全球行業規模、佔有率、趨勢、競爭、機會和預測，按類型、按技術、按產品、按應用、按最終用戶、按地區細分

Flow Cytometry in Oncology and Immunology Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Technology, By Offering, By Application, By End User, By Region
出版日期: | 出版商: TechSci Research | 英文 116 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計在2024-2028 年的預測期內，全球腫瘤學和免疫學流式細胞儀市場將以穩定的複合年成長率成長。這主要歸因於流式細胞儀在研究活動中的應用範圍不斷擴大以及新一代流式細胞儀的開發。據世界衛生組織稱，癌症是造成全球疾病負擔和死亡率的主要原因之一，而癌症預防、診斷和治療戰略仍是全球努力的方向。腫瘤學和免疫學中的流式細胞術是指測量血液、骨髓或其他組織樣本中的細胞數量、活細胞百分比和細胞的某些特徵（如大小和形狀），以及細胞表面是否存在腫瘤標誌物（如抗原）的實驗室程序。免疫腫瘤學（IO）是研究免疫系統的抗癌功能，以及開發提高免疫系統抗癌能力的治療方法。然而，對新的腫瘤學和免疫學技術/工具的需求不斷增加，這將進一步推動全球腫瘤學和免疫學流式細胞儀市場的成長。此外，技術的發展和努力尋找特異靈敏的工具來監測治療期間和治療後的免疫反應，預計也將在預測的幾年內推動市場的成長。

癌症發病率上升

在全球範圍內，癌症是最常見的死亡原因之一。全球癌症病例的增加可能是腫瘤分子診斷市場擴大的一個因素。根據美國癌症協會的數據，2021 年美國新增癌症病例180 萬例，死亡60 萬例。

由於惡性細胞的擴增，醫學專家正在加大研發力度，以創造出有助於預防和治療癌症的療法和診斷服務。癌症免疫療法正成為不同疾病階段多種腫瘤類型的標準治療方法，可提高生存率，減少疾病復發。據美國食品和藥物管理局（FDA）稱，目前正在開展多項成功實施免疫學和腫瘤學治療的臨床試驗，以評估多種癌症類型的療效，實施組合療法，從機理上了解新藥開發或確定臨床反應的免疫預測因子。因此，它們的治療和開發的療法是推動全球腫瘤學和免疫學流式細胞儀市場成長的原因。

技術進步

更先進技術的發展包括質譜流式細胞儀、成像流式細胞儀、基因組流式細胞儀和光譜流式細胞儀，這些技術通過以更高的解析度同時表徵單細胞中更多的細胞參數，擴大了研究免疫反應的能力。據研究人員稱，免疫系統可以靶向摧毀癌細胞；因此，基於免疫腫瘤學的療法涵蓋了增強癌症患者免疫反應的不同方法，包括激活效應細胞、接種腫瘤抗原疫苗、注射溶瘤病毒、阻斷抑制途徑或免疫抑制機制、使用採用性嵌合抗原受體T細胞療法以及放大保護途徑。

最新進展與產品上市

全球腫瘤學和免疫學流式細胞儀市場的成長得益於主要市場參與者的出現。例如，2022 年6 月，Becton, Dickinson 公司在國際流式細胞儀促進會（ISAC）上推出了新的細胞分揀技術。 2022 年9 月，一家公司，即Becton, Dickinson，推出了BD Research Cloud，這是一種雲端基礎軟體解決方案，旨在改善免疫學、病毒學、癌症和傳染病監測等多個領域研究人員的流式細胞儀流程，以實現更高品質的實驗和更快的理解時間。此外，2022 年2 月，Becton, Dickinson 收購了Cytognos, SL，擴大了其流式細胞儀產品組合，並獲得了Cytognos SL 約80 名科學家和專業人員的專業知識。

可用客製化

TechSci Research 可根據給定的市場數據，為公司的特定需求提供客製化服務。報告可提供以下客製化選項：

公司資訊

  • 其他市場參與者（最多五家）的詳細分析和概況。

目錄

第1 章：產品概述

  • 市場定義
  • 市場範圍
    • 覆蓋市場
    • 研究年份
    • 主要市場細分

第2 章：研究方法

  • 研究目的
  • 基準方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第3 章：執行摘要

  • 市場概述
  • 主要市場細分概述
  • 主要市場參與者概述
  • 主要地區/國家概述
  • 市場驅動因素、挑戰和趨勢概述

第4章：客戶之聲

第5章：全球腫瘤學和免疫學流式細胞儀市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型（免疫學、腫瘤學）
    • 按技術（細胞流式細胞儀、珠基流式細胞儀）
    • 按產品（試劑、儀器和耗材軟體）
    • 按應用（轉化研究、臨床研究）
    • 按最終用戶（醫院、診斷實驗室和參考實驗室、製藥和生物技術公司、學術研究機構、契約研究組織及其他）
    • 按地區（北美、歐洲、亞太地區、南美、中東和非洲）
    • 按公司（2022 年）
  • 市場地圖
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按地區

第6 章: 北美腫瘤學和免疫學流式細胞儀市場展望

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按國家
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第七章：歐洲腫瘤學和免疫學流式細胞儀市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按國家
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8 章: 亞太地區腫瘤學和免疫學流式細胞儀市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳大利亞

第9 章: 南美腫瘤學和免疫學領域的流式細胞儀市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按國家
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10 章: 中東和非洲腫瘤學與免疫學流式細胞儀市場前景

  • 市場規模與預測
    • 按價值
  • 市場佔有率與預測
    • 按類型
    • 按技術
    • 按產品
    • 按應用
    • 按最終用戶
    • 按國家
  • 中東和非洲：國家分析
    • 阿拉伯聯合大公國腫瘤學和免疫學中的流式細胞儀
    • 沙烏地阿拉伯腫瘤學和免疫學中的流式細胞術
    • 南非腫瘤學和免疫學中的流式細胞術
    • 土耳其腫瘤學和免疫學中的流式細胞術
    • 埃及腫瘤學和免疫學中的流式細胞術

第11 章：市場動態

  • 驅動因素
    • 癌症發病率上升
    • 技術進步
    • 最新發展和產品上市
  • 挑戰
    • 流式細胞儀產品成本高昂
    • 錯誤的抗體反應

第12 章：市場趨勢與發展

第13 章：競爭格局

  • 業務概述
  • 產品供應
  • 近期發展
  • 財務狀況（報告）
  • 主要人員
    • Danaher Corporation
    • Merck KGaA
    • Miltenyi Biotec
    • Neo-Genomics Laboratories, Inc.
    • Thermo Fisher Scientific Inc
    • Cell Signaling Technology, Inc
    • Becton, Dickinson and Company
    • Agilent Technologies, Inc.
    • DiaSorin SpA (Luminex Corporation)
    • OPKO Health, Inc.

第14 章：戰略建議

簡介目錄
Product Code: 15020

Global Flow Cytometry in Oncology and Immunology Market is anticipated to witness a growth of steady CAGR in the forecast period, 2024-2028. This can be ascribed due to the expansion of flow cytometry's applicability in research activities and the development of next-generation flow cytometers. According to the World Health Organization, Cancer is one of the leading causes of disease burden and mortality in the world, and strategies for cancer prevention, diagnosis, and treatment are still a global effort. Flow cytometry in oncology and immunology refers to the laboratory procedure to measure the number of cells, the percentage of live cells, and certain characteristics of cells, such as size and shape, in a sample of blood, bone marrow, or other tissue, the presence of tumor markers, such as antigens, on the surface of the cells. Immuno-oncology (IO) is the study of the immune system's functionality against cancer and the development of treatments that improve the ability of the immune system to fight the disease. However, the demand for new oncology and immunologic techniques/tools is increasing, which is further expected to drive the growth of global flow cytometry in the oncology and immunology market. Additionally, the development of technology and efforts to find specific and sensitive tools to monitor immune responses during and after therapy is thereby expected to drive the growth of the market in the forecast years.

The growing prevalence of cancer cases, the technological advancement with the highest accuracy and precision, and the growing awareness amongst the population globally are projected to propel the growth of the market. However, the high cost of products of flow cytometry equipment is expected to hamper the growth of flow cytometry in the oncology and immunology market in the forecast years.

Rising Prevalence of Cancer Cases

Globally, Cancer is one of the prevalent causes of death. The global increase in cancer cases is probably a factor in the oncology molecular diagnostics market's expansion. In the United States of America in 2021, there were 1.8 million new cases and 0.6 million cancer deaths, according to the American Cancer Society.

Medical professionals are stepping up their research and development efforts to create therapies and diagnostic services as a result of the expansion of malignant cells to aid the prevention and treatment of cancer. Cancer immunotherapy is becoming the standard of care for multiple tumor types at diverse disease stages, providing better survival with reduced disease recurrences. According to Food and Drug Administration (FDA), multiple clinical trials with successful implementation of immunology and oncology treatments are being conducted to evaluate the efficacy of treatments of multiple cancer types, to implement combinatorial therapies, to gain mechanistic insight for new drug development or to identify immune predictors of clinical response. Therefore, their treatment and developed therapies are responsible for propelling the growth of global flow cytometry in the oncology and immunology market.

Advancement in Technology

The development of more advanced technologies includes mass cytometry, imaging flow cytometry, genomic cytometry, and spectral cytometry with an expanded ability to study immune responses by characterizing more cellular parameters simultaneously in single cells with higher resolution. According to the researchers, the immune system can target and destroy cancer cells; therefore, immune-oncology-based therapies cover different approaches to boost the immune response in cancer patients, that range from activation of effector cells, vaccination with tumor antigens, administration of oncolytic viruses, blockage of inhibitory pathways or immunosuppressive mechanisms, use of adoptive chimeric antigen receptor T-cell therapy, and to amplify the protective pathways.

Recent Developments & Product Launches

The growth of global flow cytometry in the oncology and immunology market is witnessed due to the presence of major market players. For instance, in June 2022, Becton, Dickinson, and Company launched its new cell sorting technology at the International Society for Advancement of Cytometry (ISAC). In September 2022, a company, namely Becton, Dickinson, launched BD Research Cloud, a cloud-based software solution designed to improve the flow cytometry process for researchers working in a variety of fields, such as immunology, virology, cancer, and infectious disease monitoring, in order to enable higher-quality experiments with faster time to understand. Additionally, in February 2022, Becton, Dickinson acquired Cytognos, S.L. and expanded its flow cytometry portfolio, and gained the expertise of ~80 scientists and professionals at Cytognos S.L.

Market Segmentation

Global Flow Cytometry in Oncology and Immunology Market can be segmented by type, technology, offering, application, end user, region, and company. Based on type, the market can be segmented into immunology and oncology. Based on technology, the market is fragmented into cell-based flow cytometry and bead-based flow cytometry. Based on the offering, the market is segmented into reagents, instruments, and consumables software. Based on application, the market is fragmented into translational research and clinical research. Based on end users, the market is segmented into hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

Company Profiles

Danaher Corporation, Merck KGaA, Miltenyi Biotec, Neo-Genomics Laboratories, Inc., Thermo Fisher Scientific Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Agilent Technologies, Inc., DiaSorin S.p.A (Luminex Corporation), OPKO Health, Inc., etc., are some of the key players operating in the global flow cytometry in the oncology and immunology market.

Report Scope

In this report, Global Flow Cytometry in Oncology and Immunology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Flow Cytometry in Oncology and Immunology Market, By Type:

  • Immunology
  • Oncology

Flow Cytometry in Oncology and Immunology Market, By Technology:

  • Cell-based flow cytometry
  • Bead-based flow cytometry

Flow Cytometry in Oncology and Immunology Market, By Offering:

  • Reagents
  • Instruments
  • Consumables software

Flow Cytometry in Oncology and Immunology Market, By Application:

  • Translational Research
  • Clinical Research

Flow Cytometry in Oncology and Immunology Market, By End User:

  • Hospitals
  • Diagnostic Laboratories
  • Reference Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Contract Research Organizations
  • Others

Flow Cytometry in Oncology and Immunology Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Flow Cytometry in Oncology and Immunology Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Flow Cytometry in Oncology and Immunology Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Immunology, Oncology)
    • 5.2.2. By Technology (Cell-based flow cytometry, Bead-based flow cytometry)
    • 5.2.3. By Offering (Reagents, Instruments, and Consumables Software)
    • 5.2.4. By Application (Translational Research, Clinical Research)
    • 5.2.5. By End User (Hospitals, Diagnostic Laboratories, and Reference Laboratories, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others)
    • 5.2.6. By Region (North America, Europe, Asia Pacific, South America, Middle East and Africa)
    • 5.2.7. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Type
    • 5.3.2. By Technology
    • 5.3.3. By Offering
    • 5.3.4. By Application
    • 5.3.5. By End User
    • 5.3.6. By Region

6. North America Flow Cytometry in Oncology and Immunology Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Technology
    • 6.2.3. By Offering
    • 6.2.4. By Application
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Offering
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Offering
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Flow Cytometry in Oncology and Immunology Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Offering
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By End User

7. Europe Flow Cytometry in Oncology and Immunology Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Technology
    • 7.2.3. By Offering
    • 7.2.4. By Application
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Offering
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By End User
    • 7.3.2. France Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Offering
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Offering
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Offering
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Flow Cytometry in Oncology and Immunology Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Offering
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By End User

8. Asia-Pacific Flow Cytometry in Oncology and Immunology Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Technology
    • 8.2.3. By Offering
    • 8.2.4. By Application
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Offering
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By End User
    • 8.3.2. Japan Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Offering
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By End User
    • 8.3.3. India Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Offering
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Offering
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Flow Cytometry in Oncology and Immunology Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Offering
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By End User

9. South America Flow Cytometry in Oncology and Immunology Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Technology
    • 9.2.3. By Offering
    • 9.2.4. By Application
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Offering
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By End User
    • 9.3.2. Argentina Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Offering
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By End User
    • 9.3.3. Colombia Flow Cytometry in Oncology and Immunology Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Offering
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By End User

10. Middle East and Africa Flow Cytometry in Oncology and Immunology Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Technology
    • 10.2.3. By Offering
    • 10.2.4. By Application
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Offering
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By End User
    • 10.3.2. Saudi Arabia Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Offering
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By End User
    • 10.3.3. South Africa Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Offering
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By End User
    • 10.3.4. Turkey Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Type
        • 10.3.4.2.2. By Technology
        • 10.3.4.2.3. By Offering
        • 10.3.4.2.4. By Application
        • 10.3.4.2.5. By End User
    • 10.3.5. Egypt Flow Cytometry in Oncology and Immunology Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Type
        • 10.3.5.2.2. By Technology
        • 10.3.5.2.3. By Offering
        • 10.3.5.2.4. By Application
        • 10.3.5.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
    • 11.1.1. Rising Prevalence of Cancer Cases
    • 11.1.2. Advancement in Technology
    • 11.1.3. Recent Developments & Product Launches
  • 11.2. Challenges
    • 11.2.1. High Cost of the Products of the Flow Cytometry Equipment
    • 11.2.2. False antibody responses

12. Market Trends & Developments

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
    • 13.5.1. Danaher Corporation
    • 13.5.2. Merck KGaA
    • 13.5.3. Miltenyi Biotec
    • 13.5.4. Neo-Genomics Laboratories, Inc.
    • 13.5.5. Thermo Fisher Scientific Inc
    • 13.5.6. Cell Signaling Technology, Inc
    • 13.5.7. Becton, Dickinson and Company
    • 13.5.8. Agilent Technologies, Inc.
    • 13.5.9. DiaSorin S.p.A (Luminex Corporation)
    • 13.5.10. OPKO Health, Inc.

14. Strategic Recommendations